Introduction {#s1}
============

Pulmonary embolism (PE) has a high incidence and mortality is high when untreated \[[@C1]\]. The current gold standard to confirm or exclude the presence of emboli in the pulmonary arteries, computed tomography pulmonary angiography (CTPA), requires irradiation, is relatively expensive and cannot be directly applied in all patients seen in the emergency department (ED). Several strategies have been developed to reduce the number of CTPA scans needed. The most used strategy, to select the right patients for CTPA scanning, uses the Christopher algorithm and includes the use of a clinical prediction tool (such as the Wells score) and D-dimer testing \[[@C2]\]. Although its negative predictive value (NPV) is satisfying (enabling the safe exclusion of PE), its positive predictive value (PPV) is poor (*i.e.* less than 30%) \[[@C2], [@C3]\]. Therefore, the search for additional fast, cheap diagnostics to safely exclude PE in the ED without the need for CTPA continues.

The use of capnography in the exclusion of PE has been studied several times. Most of these studies focus on the usability of end-tidal carbon dioxide tension (*P*~ETCO~2~~), often combined with arterial carbon dioxide tension (*P*~aCO~2~~), to calculate the alveolar dead-space fraction (AVDSf) which represents the fraction of ventilation that is wasted on dead space. Though the results of several individual studies seemed promising \[[@C4], [@C5]\], a meta-analysis showed a pooled sensitivity of 80% for both *P*~ETCO~2~~ and AVDSf, and 73% for AVDSf alone \[[@C6]\]. Given the high mortality of untreated PE, these sensitivities are too low to justify the use of *P*~ETCO~2~~ or AVDSf in clinical practice.

In volumetric capnography, the carbon dioxide tension (*P*~CO~2~~) in exhaled air is plotted as a function of the exhaled volume ([figure 1](#F1){ref-type="fig"}). The resulting curve is often divided into three phases: 1) the anatomic dead space (containing no carbon dioxide), 2) a transition phase (in which carbon dioxide increases rapidly), and 3) a plateau resembling alveolar air (in which a slight linear increase in carbon dioxide is seen due to continuous diffusion of carbon dioxide from the capillaries into the alveoli). Extensive reviews of volumetric capnography and its potential clinical applications have been produced \[[@C7], [@C8]\].

![Example of a volumetric capnogram. A linear approximation of phase 3 of the capnogram (slope 3) is indicated by the dotted line. Carbon dioxide production (*V*~CO~2~~) can be calculated by dividing the area under the curve (AUC) of the capnogram (indicated by the grey area) by the atmospheric pressure. Arterial carbon dioxide tension (*P*~aCO~2~~) is indicated by the dashed line. Capnography variables were defined as follows: volumetric capnography parameter (CapNoPE)=(*V*~CO~2~~×slope 3)/RR; pulmonary embolism index (PE-index)=(*P*~aCO~2~~--*P*~ETCO~2~~)/slope 3; late dead-space fraction (*F*~dlate~)=1--(extrapolated *P*~CO~2~~ at 15% of TLC/*P*~aCO~2~~); alveolar dead-space fraction (AVDSf)=(*P*~aCO~2~~--*P*~ETCO~2~~)/*P*~aCO~2~~. RR: respiratory rate; *P*~ETCO~2~~: end-tidal carbon dioxide tension; *P*~CO~2~~: carbon dioxide tension; TLC: total lung capacity](00099-2018.01){#F1}

The volumetric capnogram and its phases contain more information than just *P*~ETCO~2~~. It can be hypothesised that some (or a combination) of the volumetric capnography parameters are influenced by the presence of pulmonary emboli (and thus may be useful in the exclusion of PE). The number of studies investigating the usability of volumetric capnography in the exclusion of PE is limited. P[atel]{.smallcaps} *et al*. \[[@C9]\] performed a neural network analysis on the volumetric capnogram of six subjects with PE and six subjects without PE. This analysis resulted in 17 volumetric capnography parameters which were associated with the presence of PE. In 1989, E[riksson]{.smallcaps} *et al*. \[[@C10]\] proposed a novel parameter, the late dead-space fraction (*F*~dlate~), where *F*~dlate~=1−(extrapolated *P*~CO~2~~ at an exhaled volume of 15% of the predicted total lung capacity (TLC)/*P*~aCO~2~~). They showed that *F*~dlate~ is increased in subjects with PE compared to healthy subjects and subjects with obstructive pulmonary diseases. In 2004, V[erschuren]{.smallcaps} *et al*. \[[@C11]\] compared the diagnostic accuracy of *F*~dlate~, the arterial to end-tidal carbon dioxide gradient (*P*~aCO~2~~−*P*~ETCO~2~~) and the slope of phase 3 (slope 3) of the volumetric capnogram (*i.e.* the alveolar phase). In this analysis, the *F*~dlate~ ratio seemed to have the highest diagnostic properties. The use of the slope of phase 3 seems physiologically justified as a decrease in pulmonary perfusion decreases slope 3. Some years later, V[erschuren]{.smallcaps} *et al*. \[[@C12]\] performed a larger study comparing *F*~dlate~, AVDSf and a new parameter, pulmonary embolism index (PE-index), involving the arterial to end-tidal carbon dioxide gradient and the slope of phase 3, where PE-index=(*P*~aCO~2~~−*P*~ETCO~2~~)/slope 3. Unfortunately, the volumetric capnography based parameters (PE-index and *F*~dlate~) did not show better diagnostic properties when compared with the sole ratio of *P*~ETCO~2~~ and *P*~aCO~2~~. In a recent pilot study \[[@C13]\] we proposed a novel volumetric capnography derived parameter, CapNoPE, which involves carbon dioxide production (*V*~CO~2~~; the amount of carbon dioxide exhaled per breath), slope 3 and respiratory rate (RR), such that CapNoPE=(*V*~CO~2~~×slope 3)/RR. As PE is likely to decrease slope 3 and *V*~CO~2~~, and might increase RR, we hypothesised that CapNoPE would be decreased in subjects with PE and would be independent of body weight (which is known to influence several capnography parameters). The pilot study results showed that CapNoPE was indeed significantly decreased in PE and a threshold of 1.90 Pa·min resulted in a sensitivity of 100% with a specificity of 47%. However, given the limited number of subjects included, the 95% CI values of the diagnostic accuracies were wide. As diagnostic properties are often overestimated in derivation sets, external validation is warranted \[[@C14]\]. The aim of the current study is to provide such validation by retrospectively assessing the diagnostic properties of CapNoPE for the exclusion of PE in data from the study performed by V[erschuren]{.smallcaps} *et al*. \[[@C12]\].

Methods {#s2}
=======

The original study population consisted of subjects aged \>18 years with suspected PE and elevated D-dimer levels at the ED of three academic hospitals in Brussels, Paris and Geneva, respectively and was part of a larger trial on the diagnosis of PE \[[@C15]\]. In this study, patients with suspected PE were randomised either to venous compression ultrasonography and, if negative, to CTPA, or to CTPA alone. PE was considered confirmed when shown on ultrasonography or CTPA, or when PE or deep vein thrombosis (DVT) were diagnosed within a follow-up period of 3 months.

The volumetric capnography measurements were performed between February 2005 and September 2006. Valid capnograms were obtained for 205 subjects and PE was diagnosed in 68 of them (33%). Of these, only three were diagnosed by a positive venous compression ultrasonography finding alone. Among those in whom PE was excluded during initial presentation, none were diagnosed with any thromboembolic event during the 3 month follow-up period. At the time of measurement, the observer was unaware of the diagnosis. The original study was approved by the relevant ethical committees and all participating subjects provided written, informed consent.

The volumetric capnography data of the 205 subjects included were used to calculate CapNoPE. The diagnostic properties of CapNoPE were assessed using the area under the curve (AUC) of the receiver operating characteristic (ROC) curve and compared with the ROC curves of *F*~dlate~, PE-index, AVDSf and *P*~ETCO~2~~ alone. Furthermore, sensitivity, specificity, NPV and PPV were calculated for a CapNoPE threshold of ≥1.90 Pa·min to exclude PE.

Continuous variables were expressed as mean±[sd]{.smallcaps} or median (interquartile range (IQR)) as appropriate. Categorical variables were expressed as counts with corresponding percentages. Differences in continuous variables were tested using independent sample T-tests when normally distributed or Mann--Whitney U-tests when non-normally distributed. Differences in categorical variables were tested using the Chi-squared test or Fisher exact test. Test outcomes were considered significant for p\<0.05. All analyses were performed using IBM SPSS Statistics version 22 (IBM Corp, Armonk, NY, USA).

Results {#s3}
=======

Baseline characteristics of the 205 included subjects are provided in [table 1](#TB1){ref-type="table"}. In total, 68 patients (33%) had confirmed PE. Compared to those without PE, the subjects with PE had significantly higher clinical probabilities (as depicted by the revised Geneva scores) and higher D-dimer values. They were also longer in the ED before volumetric capnography measurements were performed. Detailed characteristics (*e.g.* comorbidities and presenting symptoms) are provided in the original publication by V[erschuren]{.smallcaps} *et al*. \[[@C12]\]. The outcomes of the several volumetric capnography variables are provided in [table 2](#TB2){ref-type="table"}. All investigated capnography variables (CapNoPE, *F*~dlate~, PE-index, AVDSf and *P*~ETCO~2~~) were significantly different in the subjects with confirmed PE compared to those without PE. The ROC curves of these parameters are provided in [figure 2](#F2){ref-type="fig"}. The AUC of the ROC curve for CapNoPE was 0.71 (95% CI 0.64--0.79) and did not significantly differ from those of other parameters: PE-index 0.74 (95% CI 0.67--0.82), AVDSf 0.73 (95% CI 0.65--0.80), *F*~dlate~ 0.69 (95% CI 0.60--0.77) and *P*~ETCO~2~~ 0.72 (95% CI 0.65--0.80) ([figure 2](#F2){ref-type="fig"}). Cross-tabulation of the proposed CapNoPE threshold (1.90 Pa·min) against the diagnosis of PE is provided in [table 3](#TB3){ref-type="table"}. A total of 106 subjects had a value of CapNoPE ≥1.90 Pa·min, of which 24 were false-negatives. Of the 99 subjects with a value of CapNoPE \<1.90 Pa·min, 55 were false-positives. This resulted in a sensitivity of 64.7% (95% CI 52.2--75.9%) with a specificity of 59.9% (95% CI 51.1--68.1%), a NPV of 77.4% (95% CI 68.2--84.9%) and a PPV of 44.4% (95% CI 34.5--54.8%). TABLE 1Characteristics of the study population (n=205)**VariableSubjectsDiagnosisp-value^\#^PE (n=68)No PE (n=137)Female**108 (52.7)35 (51.5)73 (53.3)0.65**Age years**65.1±16.866.4±16.564.4±16.90.42**Height cm**169±9170±10168±80.21**Weight kg**75.4±16.876.0±14.475.2±17.90.76**Active smoker**45 (22.0)11 (16.2)34 (24.8)0.13**COPD**24 (11.7)5 (7.4)19 (13.9)0.17**Previous PE**38 (18.5)18 (26.5)20 (14.6)**0.04Heart failure**17 (8.3)4 (5.9)13 (9.5)0.41**Cancer**16 (7.8)5 (7.4)11 (8.0)0.87**Heart rate beats·min^−1^**89±2194±2286±21**0.01Pulse oximetry %**95 (92--97)94 (90--96)96 (93--98)**0.003Thoracic pain**124 (60.5)39 (57.4)85 (62.0)0.48**Dyspnoea**154 (75.1)56 (82.4)98 (71.5)0.11**Signs of DVT**24 (11.7)10 (14.7)14 (10.2)0.36**D-dimer level µg·L^−1^**1412 (921--2926)3070 (1600--5117)1080 (764--1929)**\<0.001Time in the ED h**5.0 (3.0--11.0)5.5 (3.3--14.0)5.0 (2.0--8.0)**0.03Symptoms h**72 (24--168)72 (24--168)72 (24--180)0.91**Revised Geneva score**5 (3--7)6 (5--8)4 (3--6)**\<0.001**Data are presented as n (%), mean±[sd]{.smallcaps} or median (interquartile range), unless otherwise stated. PE: pulmonary embolism; COPD: chronic obstructive pulmonary disease; DVT: deep vein thrombosis; ED: emergency department. ^\#^: p-values are for differences between subjects with and without PE. Values in bold are considered statistically significant (p\<0.05). TABLE 2Values of the arterial blood gas and volumetric capnography variables in the groups with and without PE (n=205)**VariableDiagnosisp-value^\#^PE (n=68)No PE (n=137)*P***~**aO~2~**~ **kPa**9.6±2.410.4±2.5**0.03*P***~**aCO~2~**~ **kPa**4.4±0.74.6±0.7**0.01*V***~**T**~ **mL**694±303636±3050.20**RR breaths·min^−1^**18.9±5.917.9±5.90.23***P***~**ETCO~2~**~ **kPa**3.41±0.894.09±0.71**\<0.001*V***~**Daw**~**/*V***~**T**~ **%**38.9±8.739.0±8.90.96***V***~**CO~2~**~ **mL·breath^−1^**13.4±7.014.9±9.10.24**Slope 3 kPa·L^−1^**1.94 (1.06--3.39)2.70 (1.54--5.24)**0.001PE-index mL**422 (144--1048)146 (67--286)**\<0.001*F***~**dlate**~ **%**0.73±45.7−15.2±34.1**\<0.001AVDSf %**22.1±14.111.3±9.9**0.01CapNoPE Pa·min**1.56±0.972.51±1.67**\<0.001**Data are presented as mean±[sd]{.smallcaps} or median (interquartile range), unless otherwise stated. PE: pulmonary embolism; *P*~aO~2~~: arterial oxygen tension; *P*~aCO~2~~: arterial carbon dioxide tension; *V*~T~: tidal volume; RR: respiratory rate; *P*~ETCO~2~~: end-tidal carbon dioxide tension; *V*~Daw~: anatomical dead-space volume; *V*~CO~2~~: carbon dioxide production; *F*~dlate~: late dead-space fraction; AVDSf: alveolar dead-space fraction; CapNoPE: volumetric capnography parameter. ^\#^: p-values are for differences between subjects with and without PE. Values in bold are considered statistically significant (p\<0.05). TABLE 3Cross-tabulation of the proposed threshold (1.90 Pa·min) of the new volumetric capnography parameter (CapNoPE) against the diagnosis of pulmonary embolism (PE) (n=205)**ParameterDiagnosisTotalPENo PECapNoPE \<1.90 Pa·min**445599**CapNoPE ≥1.90 Pa·min**2482106**Total**68137205 FIGURE 2Receiver operating characteristic curves for five capnography parameters. CapNoPE: volumetric capnography parameter; AUC: area under the curve; *P*~ETCO~2~~: end-tidal carbon dioxide tension; PE-index: pulmonary embolism index; *F*~dlate~: late dead-space fraction; AVDSf: alveolar dead-space fraction.

Discussion {#s4}
==========

The results confirm those of our pilot study which showed that CapNoPE is significantly decreased in patients with PE compared to those without. Furthermore, its diagnostic accuracy as expressed in the AUC of the ROC curve is similar to the earlier proposed parameters AVDSf, PE-index, *F*~dlate~ and *P*~ETCO~2~~.

The large advantage of CapNoPE over AVDSf, PE-index and *F*~dlate~ is that it does not need arterial sampling and therefore is less burdensome for the patient. On the other hand, some form of dead-space fraction is simpler for clinicians to interpret, whereas CapNoPE represents an abstract entity. Furthermore, in the presence of respiratory comorbidities such as chronic obstructive pulmonary disease (COPD), arterial parameters might be essential for differentiation between the effects of PE and the effects of the comorbidity. Diseases such as COPD are known to alter the volumetric capnogram (mainly slope 3) \[[@C16]\] and might thus affect CapNoPE. Unfortunately, the number of subjects with COPD included was too low to investigate this potential influence. Moreover, *P*~ETCO~2~~ alone also does not need arterial sampling and its diagnostic accuracy is, in the current study population with a relatively low number of subjects with respiratory comorbidities, also comparable to the more advanced parameters.

The rationale behind this study is to find an easily accessible tool (in addition to the current diagnostic strategy) to exclude PE in the ED. Volumetric capnography is easy to apply in the ED and the cut-off for CapNoPE of ≥1.90 Pa·min to exclude PE has shown promising sensitivity and specificity in a pilot study. However, the CIs of the diagnostic properties were wide, warranting further validation. Unfortunately, in the current larger dataset the proposed threshold results in a sensitivity 64.7% and a NPV of 77.4%. There are no obvious differences in patient characteristics between the population data presented here and the pilot study that seem to explain the lower diagnostic properties. Of note, there were no differences in the distribution of CapNoPE between the data here and those of the pilot study (p=0.22 for subjects with PE and p=0.43 for subjects without PE). The development of CapNoPE was based on the hypothesis that *V*~CO~2~~ and slope 3 are decreased in the presence of PE whereas the RR is likely to increase. It was reasoned that the effects of PE on each parameter alone might be too small to detect and therefore they were combined to increase the differences. Indeed, the pilot study did not show significant differences in slope 3, *V*~CO~2~~ or RR (although there was a non-significant trend towards higher RR and lower *V*~CO~2~~ in the subjects with PE), whereas the combination of these three parameters in CapNoPE was significantly decreased in PE subjects. The results presented here show no differences in either RR or *V*~CO~2~~ between the subjects with and without PE, but slope 3 is significantly decreased. The lower diagnostic properties found in the data presented here might be explained by the larger number of subjects included. As indicated earlier, the CIs of the diagnostic properties found in the pilot study were wide (due to a limited number of subjects).

Though the diagnostic properties of the proposed threshold are lower, it should be noted that the AUC of the ROC curve is well within the CI of the AUC found in the pilot study. However, given the potentially lethal consequences of PE, the NPV (77.4%) is unacceptable for the safe exclusion of PE. The ROC curve also shows that the cut-offs with an acceptable NPV (\>97%) have poor specificity (and PPV \<30%). As the PPV of the current diagnostic strategy is already 20--30%, these cut-offs would have no added value in the diagnostic workup of patients with suspected PE. This is also the case for the other capnography-derived parameters *P*~ETCO~2~~, AVDSf, PE-index and *F*~dlate~. This seems to imply that volumetric capnography alone will not be sufficient to exclude PE. One reason for this might be the extent of some emboli. As the specifications of the imaging standards improve, smaller emboli are detected. Furthermore, the imaging standards detect the presence of clots in the pulmonary circulation, not their consequences on gas exchange. Another reason for the limited diagnostic capacity of capnography might be the high variability of breathing (and thus carbon dioxide exchange). However, prolonged periods of data were recorded and averaged, and the data was only used for analysis if variability was low (as pre-specified by several strict criteria, based on tidal volume (*V*~T~), RR and *P*~ETCO~2~~) and visible inspection of the capnograms did not reveal obvious measurement errors \[[@C12]\]. This strategy is likely to have maximised the chance on representable measurements.

The current study has some limitations. As already mentioned CapNoPE is more abstract and therefore harder to interpret compared to dead-space fractions. However, all these parameters also require some level of physiologic expertise. The use of other tools to increase the PPV of the diagnostic workup of PE suspected patients, such as the age-adjusted D-dimer \[[@C17]\] or the Years algorithm \[[@C18]\], may therefore be more likely to succeed. The major limitation of this study is the relatively low number of subjects included. To be able to draw a definite conclusion on the usability of CapNoPE for the exclusion of PE, a much larger prospective trial would be required that included several respiratory and cardiovascular comorbidities. The definition of PE used in the original trial (positive CTPA or ultrasound at initial presentation, or a thromboembolic event during the 3 month follow-up period) might also appear to be a limitation. A positive venous ultrasonography finding alone, or the occurrence of a thromboembolic event during follow-up, does not necessarily imply that PE was present during the initial presentation when the volumetric capnography was performed. However, no thromboembolic events were recorded during the follow-up of subjects in whom PE was excluded at the initial presentation. Furthermore, PE was diagnosed based solely on a positive venous ultrasonography finding in only three subjects. Therefore it seems unlikely that this influenced the results of the current analysis.

Conclusion {#s4a}
----------

The capnography-derived parameter CapNoPE is significantly decreased in subjects with PE compared to subjects without. Furthermore, its overall diagnostic properties are essentially equal to the diagnostic properties of *P*~ETCO~2~~, PE-index, *F*~dlate~ and AVDSf. However, the NPV of the threshold value to exclude PE established earlier (CapNoPE ≥1.9 Pa·min) seems too low to use in clinical practice.
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